abstract |
It is intended to provide a medicine which comprises a combination of an antibody composition, wherein the content of sugar chains having no fucose bonded to the N-acetylglucosamine at the sugar chain reducing end amounts to 50% or more in the total N-glycoside bond complex sugar chains bonded to the Fc domain in the antibody composition, with at least one drug. |